For the millions of older adults living with severe aortic stenosis who face a valve replacement decision, stroke risk is a defining concern — yet precise, procedure-specific estimates have been scattered across dozens of independent studies. A pooled analysis published in Stroke now provides the most comprehensive quantification to date, offering clinicians and patients a clearer risk framework across three distinct intervention types.
Drawing on 27 studies in the primary cohort and 5 in a valve-in-valve subanalysis, the meta-analysis used mixed-effects models to generate pooled stroke proportions at multiple time horizons. For transcatheter aortic valve replacement (TAVR), the 30-day pooled stroke rate reached 3.0% (95% CI, 2.5–3.9%), with major and minor strokes each contributing roughly 1.7 percentage points. At one year, the all-stroke proportion climbed to 5.0% (95% CI, 4.0–6.0%), with major strokes accounting for 3.0%. The valve-in-valve subgroup and direct TAVR-versus-surgical AVR comparisons added further nuance not fully captured in prior single-study estimates.
This work arrives at a pivotal moment: TAVR now dominates aortic stenosis management across virtually all surgical risk categories, yet long-term cerebrovascular data remain less mature than for surgical AVR. The 5% one-year stroke rate is clinically meaningful — it is not trivial background noise but a consequential competing risk alongside heart failure and mortality. A persistent challenge in this literature is heterogeneous stroke definitions across trials; the distinction between major and minor stroke is often inconsistently applied, which can obscure true comparative safety signals. The meta-analysis itself cannot resolve that definitional inconsistency, making the pooled estimates best understood as approximate rather than precise benchmarks. Additionally, these figures predate widespread adoption of cerebral embolic protection devices, which may lower rates in contemporary practice. Overall, this is a well-constructed confirmatory synthesis — valuable for shared decision-making but unlikely to fundamentally alter current procedural guidance.